Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals

BACKGROUND: Clozapine remains the only medication licensed for treating refractory schizophrenia. However, it remains underutilized in part due to concerns regarding adverse events. SOURCES OF DATA: Published literature. AREAS OF AGREEMENT: Common adverse events during clozapine treatment include se...

Descripción completa

Detalles Bibliográficos
Autores principales: Flanagan, R J, Lally, J, Gee, S, Lyon, R, Every-Palmer, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585831/
https://www.ncbi.nlm.nih.gov/pubmed/32885238
http://dx.doi.org/10.1093/bmb/ldaa024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585831/
https://www.ncbi.nlm.nih.gov/pubmed/32885238
http://dx.doi.org/10.1093/bmb/ldaa024

Ejemplares similares